Monopar Therapeutics Inc Stock Price, News & Analysis

Monopar Therapeutics (MNPR) reported its Q4 and full-year 2024 financial results, highlighting a significant year marked by key developments. The company raised over $55 million in Q4 2024 through public offerings and private placements. Cash position stood at $60.2 million as of December 31, 2024, expected to fund operations through 2026.

Key developments include the in-licensing of ALXN1840 for Wilson disease with plans to submit an NDA in early 2026, and the initiation of two first-in-human radiopharma Phase 1 trials. The company reported a Q4 2024 net loss of $10.9 million ($2.23 per share) compared to $1.8 million in Q4 2023. Full-year 2024 net loss was $15.6 million ($4.11 per share) versus $8.4 million in 2023.

R&D expenses increased to $9.9 million in Q4 2024, primarily due to ALXN1840 in-licensing costs. G&A expenses rose slightly to $1.2 million in Q4 2024 from $0.9 million in Q4 2023.

Monopar Therapeutics has joined Rosalind Franklin University's Helix 51 biomedical incubator community. The clinical-stage biotech company is developing personalized radiopharmaceuticals for cancer diagnosis and treatment, along with a late-stage drug for Wilson Disease.

The company will utilize Helix 51's labs and resources to advance its research objectives. Radiopharmaceuticals, which selectively target cancer cells with radioisotopes, are important in nuclear medicine, enabling precise diagnosis and treatment while minimizing damage to healthy tissues.

Helix 51 is Lake County, Illinois' only wet-and dry-lab based incubator, situated in a region hosting over 122 bioscience companies and 33,000 bioscience jobs. The facility is part of RFU's Innovation and Research Park, which offers research space and core facilities for drug, device, and diagnostic R&D.

Monopar Therapeutics (Nasdaq: MNPR) announced the pricing of a combined public offering and private placement totaling $40 million. The offering includes 798,655 shares of common stock at $23.79 per share and pre-funded warrants for 882,761 shares at $23.789 per warrant. The transaction, expected to close around December 23, 2024, features participation from notable investors including RA Capital Management, Janus Henderson Investors, Adage Capital Partners LP, and ADAR1 Capital Management. The company plans to use proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital.

Monopar Therapeutics (Nasdaq: MNPR) has announced the first-ever patient dosing of MNPR-101-Lu, a novel therapeutic radiopharmaceutical. The treatment combines MNPR-101 antibody targeting uPAR with lutetium-177 radioisotope. The first patient, who has metastatic pancreatic cancer, received the treatment under a compassionate use protocol in the US. The intravenous infusion was well-tolerated with no serious adverse reactions reported.

Prior to treatment, the patient's cancer was imaged using MNPR-101-Zr, showing uPAR expression. The company is currently conducting two Phase 1 clinical studies in Australia, evaluating MNPR-101-Zr for imaging and MNPR-101-Lu for treatment of advanced solid tumors.

Monopar Therapeutics (Nasdaq: MNPR) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. CEO Chandler Robinson will engage in a fireside chat and one-on-one meetings at the event. The presentation is scheduled for December 5, 2024, from 10:30-10:55 am Eastern Time at the Lotte New York Palace in New York. Monopar is a clinical-stage biotechnology company that develops innovative treatments for patients with unmet medical needs.

Monopar Therapeutics (Nasdaq: MNPR) reported Q3 2024 financial results and recent developments. Key highlights include the in-licensing of ALXN-1840, a late-stage Wilson disease drug candidate from Alexion, AstraZeneca Rare Disease. The company has two active radiophharma clinical trials enrolling patients with advanced solid cancers. A recent capital raise through a public offering generated net proceeds of $17.7 million. Q3 2024 showed a net loss of $1.3 million ($0.37 per share), compared to $2.0 million ($0.69 per share) in Q3 2023. Cash position was $6.0 million as of September 30, 2024, with current funds projected to sustain operations into first half of 2026.

Monopar Therapeutics (Nasdaq: MNPR) has closed its previously announced public offering of common stock, raising $19.2 million in gross proceeds. The shares were priced at $16.25 per share. Notable participants included Janus Henderson Investors and RA Capital Management. Rodman & Renshaw served as the exclusive placement agent. The company plans to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital. The offering was made through a shelf registration statement previously filed with the SEC.

Monopar Therapeutics (Nasdaq: MNPR) has announced the pricing of a public offering of common stock at $16.25 per share, aiming to raise approximately $19.2 million in gross proceeds. The offering, expected to close on October 30, 2024, features participation from notable investors including Janus Henderson Investors and RA Capital Management. Rodman & Renshaw serves as the exclusive placement agent. The company plans to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital.

Monopar Therapeutics (Nasdaq: MNPR) announced plans for a best efforts public offering of common stock. The clinical-stage biotech company intends to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital. Rodman & Renshaw is serving as the exclusive placement agent. The offering will be conducted under a previously filed S-3 registration statement. The final terms will be disclosed in a prospectus supplement to be filed with the SEC.